Disc Medicine (NASDAQ: IRON) legal chief exercises options, sells 1,000 shares

Rhea-AI Filing Summary

Disc Medicine, Inc.'s Chief Legal Officer, Rahul Khara, reported an option exercise and share sale in company stock. On January 20, 2026, he exercised a stock option for 1,000 shares of common stock at an exercise price of $13.5 per share, converting derivative securities into common shares. On the same day, he sold 1,000 shares of common stock at a price of $69.74 per share, leaving him with 37,793 shares of common stock held directly and 21,270 stock options remaining.

The filing states that these transactions were carried out under a Rule 10b5-1 trading plan adopted on September 23, 2025, which is a pre-arranged plan designed to allow insiders to trade shares according to preset instructions. The underlying option shares vest in 48 equal monthly installments following December 29, 2022, conditioned on his continued service.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Khara Rahul

(Last) (First) (Middle)

C/O DISC MEDICINE, INC.

321 ARSENAL STREET, SUITE 101

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Disc Medicine, Inc. [ IRON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/20/2026		M(1)		1,000	A	$13.5	38,793	D
Common Stock	01/20/2026		S(1)		1,000	D	$69.74	37,793	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$13.5	01/20/2026		M(1)			1,000	(2)	12/28/2032	Common Stock	1,000	$0	21,270	D

Explanation of Responses:

1. The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on September 23, 2025.

2. The shares underlying this option vest in 48 equal monthly installments following December 29, 2022, subject to the Reporting Person's continued service on each such vesting date.

	By: /s/ Rahul Khara	01/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Disc Medicine (IRON) report for Rahul Khara?

The Chief Legal Officer, Rahul Khara, reported exercising a stock option for 1,000 shares of common stock at $13.5 per share on January 20, 2026, and selling 1,000 shares of common stock at $69.74 per share on the same date.

How many Disc Medicine (IRON) shares does Rahul Khara hold after this Form 4?

After the reported transactions, Rahul Khara directly holds 37,793 shares of common stock and 21,270 stock options of Disc Medicine, Inc.

Was the Disc Medicine (IRON) insider trade made under a Rule 10b5-1 plan?

Yes. The filing states that the transactions were effected under a Rule 10b5-1 trading plan adopted on September 23, 2025, which allows pre-scheduled trades by insiders.

What is the vesting schedule for Rahul Khara’s Disc Medicine (IRON) stock option?

The shares underlying the reported stock option vest in 48 equal monthly installments following December 29, 2022, subject to Rahul Khara’s continued service on each vesting date.

What types of securities were involved in this Disc Medicine (IRON) Form 4?

The Form 4 reports a stock option (right to buy) with an exercise price of $13.5 per share and the related common stock acquired upon exercise and then sold.

Is this Disc Medicine (IRON) Form 4 filed by one reporting person or a group?

The Form 4 is marked as filed by one reporting person, identifying Rahul Khara as an officer with the title Chief Legal Officer.